Alteration of Fc-fusion protein serum half-lives by mutagenesis
AssigneePDL BioPharma, Inc.
InventorsPaul R. Hinton, Naoya Tsurushita
Life of this patent
Estimating the term…
Abstract
The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
Claims18
A modified Fc-fusion protein wherein at least one amino acid residue from the heavy chain constant region selected from the group consisting of residues 250, 314, and 428 is different from that present in the unmodified Fc-fusion protein, and wherein amino acid residues are numbered by the EU numbering system.
(canceled)
An Fc-fusion protein comprising an Fc region substantially identical to that of a naturally occurring class IgG antibody wherein at least one amino acid residue selected from the group consisting of residues 250, 314, and 428 is different from that present in the naturally occurring class IgG antibody, and wherein amino acid residues are numbered by the EU numbering system.
-24. (canceled)
Dependencies are inferred from the claim text.